Gujarat Kidney and Super Speciality Ltd
- Market cap
- ₹ 1,403 Cr.
- P/E
- 85.4x
- P/B
- 5.6x
- 52-week range
- 98.36 – 209.8
- ROE
- 11%
- ROCE
- 14%
- Dividend yield
- 0%
- Debt / equity
- 0.12
- Sector
- Healthcare Services
- Industry
- Hospital
- Listed on
- NSE, BSE
About
Gujarat Kidney and Super Speciality Ltd is a regional healthcare company. The Company operates a chain of mid-sized multispecialty hospitals, providing integrated healthcare services, with a focus on secondary and tertiary care. The Company offers a comprehensive range of healthcare services, such as General Medicine, General Surgery, Laparoscopic Surgery, Metabolic and Obesity Surgery, In vitro fertilization (IVF), Obstetrics and Gynecology (OBGY), Ortho, Joint Replacement, Arthroscopy, Endocrinology, Diabetology, Pulmonology, Intensivist, Skin and VD, Radiology, Pathology, Psychiatrist, Pediatric, Ophthalmology, ear, nose, and throat (ENT), Physiotherapy, Dietician, Urology, Cardiology, Nephrology, Neurology, Neuro Surgery, Oncology, Onco Surgery, Renal Transplant, Vascular Surgery, Gastroenterology, Gastro Surgery, Plastic Surgery, and Pediatric Surgery. The Company operates seven multi-specialty hospitals and four pharmacies within its hospitals.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Hospital: 41 companies →Gujarat Kidney and Super Speciality Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)85.4 against a typical 48.9: pricier than most peers (1st = cheapest).28th of 40
- Sales growth+124.7% against a typical +21.1% from a year earlier.3rd of 34
- Profit growth−1.5% against a typical +13% from a year earlier.24th of 31
- Share price, 3 months+35.4% against a typical −8.8%.2nd of 35
- Size₹ 1,403 Cr. market value against a typical ₹ 1,306.7 Cr. (1st = largest).18th of 36
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 4 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 14 Aug 2026 | Financial Results | To consider and approve the unaudited standalone and consolidated financial results for the period ended Jun 30, 2026 |
| 28 May 2026 | Financial Results | To consider and approve the audited financial results for the quarter and year ended March 31, 2026 and other matters |
| 14 Feb 2026 | Financial Results/Other business matters | The Company has informed the Exchange that a Board meeting to be held on February 13, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on February 14, 2026, To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 13 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 9 | 12 | 10 | 15 | 13 | 23 | 31 | 34 |
| Expenses | 5 | 7 | 7 | 7 | 8 | 16 | 24 | 26 |
| Operating Profit | 5 | 5 | 3 | 9 | 5 | 7 | 6 | 8 |
| OPM % | 51.7% | 39% | 26.7% | 56.5% | 39.6% | 29.7% | 20.6% | 24.4% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Profit before tax | 4 | 4 | 2 | 7 | 4 | 5 | 5 | 7 |
| Tax % | 26.3% | 29.7% | 16.9% | 27.8% | 28.5% | 26.4% | −3% | 23.6% |
| Net Profit | 3 | 3 | 1 | 5 | 3 | 4 | 5 | 5 |
| EPS in Rs | 18.39 | 15.53 | 0.23 | 0.85 | 0.47 | 0.37 | 0.64 | 0.66 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 119%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 1,058%
- TTM
- 37%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 16%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Gujarat Kidney and Super Speciality Ltd | ₹ 171.96 | ₹ 1,403 Cr. | 85.4x | 5.6x | 11% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 65.5x | 13.5x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 72.3x | 10x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102x | 9.2x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48x | 9.1x | 19.9% | 10.3% |
Management
- Pragnesh Yashwantsinh Bharpoda
- Executive Chairman, Managing Director
- Bhavikaben Mitesh Patel
- Chief Financial Officer
- Bhartiben Pragnesh Bharpoda
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.